Biotech and Pharmaceuticals Pharmaceuticals

  • Larry the Cable Guy

    I asked Larry about all kinds of topics, from the presidential debates to the U.S. economy to his own personal investments.

  • Hong Kong's IPO Market in 'Deep Recession': Pro

    Francis Lun, Managing Director at Lyncean Holdings says Hong Kong's IPO market is in a deep recession, hurt by a slump in China and the euro zone. He adds the market's recovery will be slow.

  • Healthcare cost

    TheStreet.com reports on Sarepta Therapeutics and the outstanding results from the eteplirsen study in Duchenne muscular dystrophy announced today.

  • Healthcare cost

    Thanks to several rounds of cost cutting and new product launches, cash balances across the pharma sector are increasing — because one analyst said we should see more cash being returned to shareholders via dividend.

  • Hunt For Yield... In Pharma?

    CNBC's Seema Mody shares several dividend plays for investors seeking yield in the pharma sector.

  • Biotech

    TheStreet reports that Peregrine stock plunged when company reported discrepancies in the cancer drug bavituximab study.

  • Biotech

    Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.

  • Arena Pharmaceuticals

    Vivus announced the commercial launch of its weight-loss pill Qsymia Monday, beating rival Arena Pharmaceuticals to first reach the bulging waistbands of obese Americans.  TheStreet.com reports.

  • Abbott Laboratories

    Option action lit up yesterday in Abbott Laboratories, which has been a solid performer for the last year.

  • AstraZeneca Poaches Genentech Boss From Roche

    AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.

  • Healthcare cost

    Idenix Pharmaceuticals shares fell 10 percent Monday after the U.S. Food and Drug Administration placed a second of the company's experimental hepatitis C drugs on clinical hold due to heart safety concerns. TheStreet.com reports.

  • Eli Lilly & Co. corporate headquarters stand in Indianapolis, Indiana, U.S., on Monday, May 21, 2012.

    A treatment for Alzheimer's disease from drugmaker Eli Lilly yielded promising signs in late-stage research, even though the drug failed to slow mental decline in two separate studies of patients with mild-to-moderate cases of the mind-robbing condition.

  • Merck

    Now is the time to own stocks with big dividends, one analyst says. In health care, that means large cap pharmaceuticals. TheStreet.com reports.

  • Apple Store

    Apple has quietly told its store workers to match discounts on the iPhone 4 and iPhone 4S from approved major retailers and carriers like Sprint Nextel, which is currently offering a $50 break. Apple won’t offer the discounts automatically; customers have to ask.

  • Think you can’t own growth stocks in this market? Think again.

  • bristol_myers_squibb.jpg

    FBI agents arrested Robert Ramnarine, a Bristol-Myers Squibb executive, on Thursday, and criminally charged him with insider trading in call options, court papers show.

  • bristol_myers_squibb.jpg

    Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.

  • bank_building_200.jpg

    Large regional banks continue to outperform the money center banks, despite the compelling stock price multiples for the largest bank holding companies.

  • Horizon Pharma should hear good news from U.S. regulators Thursday about its rheumatoid arthritis drug Rayos. Full approval of the drug should be in the bag.

  • bristol_myers_squibb.jpg

    Generic competition will be the major headwind that Bristol-Myers Squibb faces this quarter, as its blockbuster drug Plavix — which saw U.S. sales peak at $7 billion last year — went off patent in May.